A meta-analysis of 62 studies involving 2,439 spinal cord injury patients examined stem cell therapy outcomes. The data is more nuanced than the headlines — here's what it actually shows.
A systematic review and meta-analysis published in BMC Medicine (Springer, 2022) analyzed 62 studies involving 2,439 patients with spinal cord injury (SCI) who received stem cell therapy. This is the most comprehensive published analysis of stem cell therapy outcomes for SCI available in peer-reviewed literature.
The Research Behind This Article
A systematic review and meta-analysis published in BMC Medicine (Springer, 2022) analyzed 62 studies involving 2,439 patients with spinal cord injury (SCI) who received stem cell therapy. This is the most comprehensive published analysis of stem cell therapy outcomes for SCI available in peer-reviewed literature.
Chinese research centers contributed significantly to the study pool, reflecting China's position as one of the highest-volume countries for SCI stem cell trials globally.
Key Outcomes: What the Data Shows
Neurological Function (ASIA Impairment Scale)
The American Spinal Injury Association (ASIA) impairment scale is the standard international classification for spinal cord injury severity, ranging from ASIA A (complete — no motor or sensory function) to ASIA E (normal).
Across the 62 studies, stem cell therapy resulted in improvement of at least one ASIA grade in 48.9% of patients. This means roughly half of treated patients experienced a meaningful neurological improvement — the ability to detect sensation, move a limb, or regain function that was previously absent.
Organ Function Recovery
- Urinary system function improvement: 42.1% of patients
- Gastrointestinal function improvement: 52.0% of patients
For SCI patients, bladder and bowel function are among the most impactful quality-of-life concerns. These figures suggest clinically meaningful functional benefits beyond the motor/sensory improvements captured by ASIA grading.
What Types of Stem Cells Were Used?
The studies included in the meta-analysis used various cell types, primarily:
- Mesenchymal stem cells (MSCs) — from bone marrow, umbilical cord, and adipose (fat) tissue
- Olfactory ensheathing cells (OECs)
- Neural stem cells (NSCs)
- Schwann cells
MSCs were the most commonly studied, consistent with their broader clinical trial profile in China and globally.
Safety Profile
Across the 62 studies, serious adverse events attributable to stem cell therapy were uncommon. The most frequently reported side effects were transient: fever, headache, and localized pain at the injection site. No studies reported tumor formation attributable to stem cell treatment.
It is important to note that the safety profile across studies reflects a heterogeneous set of trial designs and cell preparations — not all stem cell products are equivalent in safety or efficacy.
XellSmart: A Chinese Company Taking SCI Therapy Global
Chinese biopharmaceutical company XellSmart Biopharmaceutical is developing allogeneic iPSC-derived regenerative cell therapy for both ALS and spinal cord injury. In 2024:
- XellSmart received approval from China's National Medical Products Administration for the first nationally registered clinical study of iPSC-derived cells (XS228) for ALS
- The US FDA granted approval for Phase I clinical trials of the same iPSC-derived therapy for both ALS and spinal cord injury in the United States
This dual approval — in both China and the US — for the same iPSC therapy product represents a significant validation of China's cell therapy research quality.
What Patients Should Realistically Expect
A 48.9% neurological improvement rate sounds encouraging — but the research has important limitations to understand:
- Improvements range from a single ASIA grade step (e.g., A to B, meaning partial sensation returns) to more substantial recovery — the data does not distinguish between these
- Study populations varied in injury level, timing from injury, and injury completeness — factors that significantly affect outcomes
- There is no randomized controlled trial with a placebo arm in this dataset — some "improvement" may reflect natural recovery
- Results apply to patients in registered clinical trials, not commercial "stem cell tourism" programs
The most favorable outcomes in the literature are consistently seen in patients with incomplete injuries, treated within 6 months of injury.
Sources: BMC Medicine (Springer), 2022 (doi:10.1186/s12916-022-02482-2); XellSmart PR Newswire, 2024; BioMed Research International, 2025 (PMC12547621).